← SynDRA
CC-401
SynDRA canonical compound SYN0025687 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | MAPK8 |
|---|
| Mechanism of action | JNK inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MAPK8 INHIBITOR
- c-Jun N-terminal kinase 1 inhibitor
- MAPK9 INHIBITOR
- c-Jun N-terminal kinase 2 inhibitor
- MAPK10 INHIBITOR
- c-Jun N-terminal kinase 3 inhibitor
- MELK INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- DYRK3
- CLK4
- CSNK1A1
- CSNK1D
- CSNK1E
- CSNK1G1
- CSNK1G2
- CSNK1G3
- CSNK2A2
- DYRK1A
- DYRK1B
- DYRK2
- FECH
- CLK1
- GAK
- GSK3B
- JAK1
- MAP4K4
- MYLK3
- NQO2
- PRKD2
- PRKD3
- SYK
- TNIK
- TYK2
- CLK2
- YJ005
- BMP2K
- PLK4
- PDGFRB
- PDXK
- PEBP1
- PFKP
- PGRMC1
- PHKG2
- PIM1
- PIM2
- PIP4K2A
- PIP4K2C
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- COMT
- CP2D6
- CP3A7
- GAMT
- GNMT
- HNMT
- IP6K1
- JAK2
- JAK3
- KSYK
- NNMT
- NSD2
- PNMT
Cross-references
Synonyms
- CC 401
- UNII-NOE38VQA1W
- NOE38VQA1W
- 3-(3-(2-(piperidin-1-yl)ethoxy)phenyl)-5-(1H-1,2,4-triazol-5-yl)-1H-indazole
- 3-(3-(2-(piperidin-1-yl)ethoxy)phenyl)-5-(1H-1,2,4-triazol-3-yl)-1H-indazole
- 3-[3-[2-(1-PIPERIDINYL)ETHOXY]PHENYL]-5-(1H-1,2,4-TRIAZOL-5-YL)-1H-INDAZOLE
- C22H24N6O
- PubChem22434
- SCHEMBL4604749
- CHEMBL1614713
- CHEBI:91437
- DTXSID40192650
- MolPort-044-561-531
- MolPort-021-804-942
- BCPP000298
- BCP01960
- ZINC38836256
- RS0046
- HY-13022A
- AKOS027251057
- AKOS027336636
- DB12432
- BCP9000495
- CS-1955
- CC401
- CC401 cpd
- RefChem:124080
- JNK Inhibitor CC-401
- DTXCID80115141
- orb1704635
- SCHEMBL4607855
- SCHEMBL29357538
- SCHEMBL30290855
- EX-A3583A
- GTPL11457
- HMS3672K03
- BDBM50248942
- NSC800068
Look up CC-401 in the interactive SynDRA portal →